Company
Regeneron
Regeneron has 36 drugs tracked on RxWires: 5 post-market, 12 in Phase 3, 1 in Phase 2/3, 6 in Phase 2, 4 in Phase 1/2, 8 in Phase 1.
- Ticker
- REGN
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Alirocumab | Post-Market | Myocardial Infarction |
| Aflibercept | Post-Market | Fibrovascular Pigment Epithelial Detachment |
| Dupixent | Post-Market | Atopic Dermatitis |
| Intravitreal Aflibercept Injection (IAI) | Post-Market | Age - Related Macular Degeneration (AMD) |
| Linvoseltamab | Post-Market | Relapsed/Refractory Multiple Myeloma (RRMM) |
| REGN7508 | Phase 3 | Atrial Fibrillation (AF) |
| Dupilumab | Phase 3 | Atopic Dermatitis |
| fianlimab | Phase 3 | Melanoma |
| REGN-2Cat | Phase 3 | Allergic Conjunctivitis |
| Odronextamab | Phase 3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) |
| Mibavademab | Phase 3 | Generalized Lipodystrophy |
| Rilonacept | Phase 3 | Gout |
| Suptavumab 30 mg/kg | Phase 3 | Respiratory Syncytial Virus Infections |
| Ravulizumab | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria |
| Pozelimab | Phase 3 | Age-related Macular Degeneration (AMD) |
| ALN-CIDEB | Phase 3 | Metabolic Dysfunction-Associated Steatotic Liver Disease |
| VEGF Trap-Eye 2.0mg | Phase 3 | Macular Edema Secondary to Central Retinal Vein Occlusion |
| Fasinumab | Phase 2/3 | Low Back Pain |
| Olatorepatide | Phase 2 | Hidradenitis Suppurativa |
| Ubamatamab | Phase 2 | Ovarian Cancer |
| Cemiplimab | Phase 2 | Pleural Mesotheliomas |
| REGN5381 | Phase 2 | Heart Failure |
| ALN-HSD | Phase 2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) |
| Fianlimab+cemiplimab | Phase 2 | Melanoma |
| REGN10597 | Phase 1/2 | Melanoma |
| REGN475 | Phase 1/2 | Osteoarthritis of the Knee |
| REGN17372+Linvoseltamab | Phase 1/2 | Relapsed Refractory Multiple Myeloma (RRMM) |
| REGV131 | Phase 1/2 | Hemophilia B |
| Fasinumab AI | Phase 1 | Osteoarthritis, Knee |
| REGN1500 | Phase 1 | Hypertriglyceridemia |
| Arm 1 cemiplimab | Phase 1 | Hepatocellular Carcinoma |
| REGN1033(SAR391786) | Phase 1 | Healthy Volunteers |
| CMP-001 | Phase 1 | Malignant Melanoma |
| REGN7999 | Phase 1 | Healthy |
| ziv-aflibercept | Phase 1 | Cancer |
| REGN20423 | Phase 1 | Atopic Dermatitis |
Latest
Follow Regeneron on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.